Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – March 2022

Pages: 14 Published: March 07, 2022 Report Code: GDHCHT311

The COVID-19 clinical and commercial analyzer is an interactive excel-based tool that scores leading pipeline-stage vaccines and therapeutics on a range of clinical and commercial parameters based on available clinical data.

Which are the key pipeline stage therapeutics in the COVID-19 clinical and commercial analyzer market?

The key pipeline stage therapeutics in the COVID-19 clinical and commercial analyzer market are remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, Paxlovid (nirmatrelvir + ritonavir), bebtelovimab, evusheld (tixagevimab + cilgavimab), molnupiravir, baricitinib, casirivimab + imdevimab, bamlanivimab + etesevimab, convalescent plasma, regdanvimab, sarilumab, eculizumab, chloroquine/hydroxychloroquine, SNG001, Octagam, leronlimab, lenzilumab, bamlanivimab, aviptadil, opaganib, and ensovibep.

COVID-19 clinical and commercial analyzer market, by pipeline stage therapeutics

COVID-19 clinical and commercial analyzer market, by pipeline stage therapeutics

For more pipeline stage therapeutic insights, download a free sample

Which are the key pipeline stage vaccines in the COVID-19 clinical and commercial analyzer market?

The key pipeline stage vaccines in the COVID-19 clinical and commercial analyzer market are Comirnaty (BNT162b2), BBIBP-CorV, Spikevax (mRNA-1273), Sputnik V, EpiVacCorona, AZD1222 (ChAdOx1), NVX-CoV2373, Covaxin (BBV152), Ad5-nCoV, CoronaVac, Ad26COV2.S, ZF-2001, VLA-2001, SCB-2019, MT-2766, INO-4800, SP-0253, ARCT-021, VXA-CoV2-1, CVnCoV, V-590, and V-591.

COVID-19 clinical and commercial analyzer market, by pipeline stage vaccines

COVID-19 clinical and commercial analyzer market, by pipeline stage vaccines

For more pipeline stage vaccine insights, download a free sample

Who are the key players in the COVID-19 clinical and commercial analyzer market?

The key players in the COVID-19 clinical and commercial analyzer market are Inovio, Moderna, Regeneron, Novavax, Merck, Pfizer, Sanofi, GSK, Gilead, Chugai, Roche, AstraZeneca, Johnson & Johnson, Lilly.

Market report scope

Key pipeline stage therapeutics remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, Paxlovid (nirmatrelvir + ritonavir), bebtelovimab, evusheld (tixagevimab + cilgavimab), molnupiravir, baricitinib, casirivimab + imdevimab, bamlanivimab + etesevimab, convalescent plasma, regdanvimab, sarilumab, eculizumab, chloroquine/hydroxychloroquine, SNG001, Octagam, leronlimab, lenzilumab, bamlanivimab, aviptadil, opaganib, and ensovibep
Key pipeline stage vaccines Comirnaty (BNT162b2), BBIBP-CorV, Spikevax (mRNA-1273), Sputnik V, EpiVacCorona, AZD1222 (ChAdOx1), NVX-CoV2373, Covaxin (BBV152), Ad5-nCoV, CoronaVac, Ad26COV2.S, ZF-2001, VLA-2001, SCB-2019, MT-2766, INO-4800, SP-0253, ARCT-021, VXA-CoV2-1, CVnCoV, V-590, and V-591
Key companies Inovio, Moderna, Regeneron, Novavax, Merck, Pfizer, Sanofi, GSK, Gilead, Chugai, Roche, AstraZeneca, Johnson & Johnson, Lilly

Scope

This analyzer includes:

  • Catalyst: Description of the most recent events impacting the COVID-19 R&D competitive landscape that are accounted for in the analysis
  • Scope of Coverage and Methodology: Discussion of product inclusion criteria and outline of rationale and assumptions
  • Clinical and Commercial Analyzer: Each asset is scored on a set of characteristics that will determine their post-launch success, including clinical features such as efficacy, safety, and dosing regimen and commercial attributes such as price, company reputation, and marketing and sales force strength
  • Competitive Assessment: Visual representation of the results of the analyzer, depicting how the leading candidates compete
  • Product Dashboard: Compilation of all key product features, plus a proprietary SWOT analysis of each product
  • Clinical Data Summary: Listing of published clinical data for all products included in the analysis

Key Highlights

Competitive Assessment: Visual representation of the results of the analyzer, depicting how the leading candidates compete.

Product Dashboard: Compilation of all key product features, plus a proprietary SWOT analysis of each product.

Clinical Data Summary: Listing of published clinical data for all products included in the analysis.

Reasons to Buy

  • With the constantly evolving COVID-19 outbreak, players need rapidly updated and detailed information on the potential for success for emerging vaccines and therapies. GlobalData’s COVID-19 Clinical and Commercial Analyzer will allow clients to:
  • View scoring of assets which will impact their success in this dynamic field, with characteristics scored including clinical features such as safety and efficacy, and commercial features such as price and company reputation and marketing capabilities.
  • Two important features of this are that the scores are easily visualized in a chart clearly depicting where different assets stand in the field. Further, the scoring sheet is live, meaning that clients can change scoring parameters based on their individual needs and preferences.
  • Access to dashboards detailing out basic information for these agents such as mechanism of action, as well as GlobalData’s take on these assets, including SWOT analyses, with further linkage to summaries of available published clinical data for assets.

Key Players

Inovio, Moderna, Regeneron, Novavax, Merck, Pfizer, Sanofi, GSK, Gilead,Chugai, Roche, AstraZeneca, Johnson & Johnson

Table of Contents

Table of Contents (PowerPoint Deck)

1 Executive Summary

1.1 Report Scope

1.2 Navigate the COVID-19 Outbreak with GlobalData Pharma’s COVID-19 Dashboard

1.3 Monitor the COVID-19 Outbreak with GlobalData Epidemiology Indicators

2 Epidemiology

2.1 Epidemiology: Snapshot as of March 25, 2020

2.2 Epidemiology: Disease Trajectory as of March 25, 2020

2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020

2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020

2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020

2.6 Epidemiology Forecast: United States

3 Pipeline Overview

3.1 Pipeline Therapeutics: Breakdown by Phase

3.2 Pipeline Therapeutics: Breakdown by Molecule Type

3.3 Pipeline Therapeutics: Breakdown by Type of Developer

3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I – III)

3.5 Pipeline Therapeutics: Preclinical-Stage Candidates

3.6 Pipeline Therapeutics: Currently Available Data

3.7 Pipeline Vaccines: Breakdown by Phase

3.8 Pipeline Vaccines: Breakdown by Developer Type

3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

4 Pipeline Overview

4.1 Pipeline Therapeutics: Breakdown by Phase

4.2 Pipeline Therapeutics: Breakdown by Molecule Type

4.3 Pipeline Therapeutics: Breakdown by Type of Developer

4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I – III)

4.5 Pipeline Therapeutics: Preclinical-Stage Candidates

4.6 Pipeline Therapeutics: Currently Available Data

4.7 Pipeline Vaccines: Breakdown by Phase

4.8 Pipeline Vaccines: Breakdown by Developer Type

4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

5 Clinical Trials

5.1 Clinical Trials: Breakdown by Phase

5.2 Clinical Trials for Therapeutics and Vaccines

5.3 Clinical Trials: Overview by Region

5.4 Clinical Trials for Therapeutics: Leading Sponsors

5.5 Clinical Trials: Leading Industry Sponsors

5.6 Trends in Trial Design

6 Deal-making Trends

6.1 Deal-making Trends

7 Social Media Trends

7.1 Key Twitter Chatter

7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve

8 Key Findings

8.1 Key Findings

9 Appendix

9.1 Sources

9.2 Methodology

9.3 About the Authors

10 About GlobalData

10.1 Contact Us

Frequently Asked Questions

Enquire Before Buying
$2495

Can be used by individual purchaser only

$7485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.